Evergraf 0.25Mg Tablet

Evergraf 0.25Mg Tablet is included in a class of medications called kinase inhibitors that treats cancer by stopping cancer cells from reproducing and cutting off blood supply to the cancer cells. Evergraf 0.25Mg Tablet decreases the action of the immune system. This may result in increased risk of developing infection or certain types of cancer such as lymphoma, skin cancer, etc.

Evergraf 0.25Mg Tablet (Afinitor) is used for the treatment of advanced renal cell carcinoma (after all other treatments have failed), a certain type of advanced breast cancer(after unsuccessful treatment using other medications), a certain type of cancer of the pancreas that has spread too much and cannot be treated with surgery, kidney tumours in people with tuberous sclerosis complex (TSC; a genetic condition that causes tumours to grow in multiple organs) and subependymal giant cell astrocytoma (SEGA; a type of brain tumour) in adults and children 1 year of age and older who have TSC. Evergraf 0.25Mg Tablet (Zortress) is used with other medications to prevent transplant rejection in certain adults who have received kidney transplants. Evergraf 0.25Mg Tablet may increase the risk of developing a blood clot that may cause you to lose the transplanted kidney and of kidney damage, especially when Evergraf 0.25Mg Tablet is used along with certain doses of cyclosporine (also used to suppress the immune system).

Some side effects may include infection with symptoms like sore throat, chills, fever, frequent and painful urination, or unusual itching, night sweats, unexplained weight loss, unusual growths or lumps and swollen lymph nodes.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Breast Cancer

• Pancreatic Cancer

• Lung Cancer

• Kidney Cancer

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Weakness

• Sinus Inflammation

• Infections

• Fever

• Cough

• Fatigue

• Stomatitis (Inflammation Of The Mouth)

• Otitis Media (Infection Of Ear)

• Diarrhoea

• Upper Respiratory Tract Infection

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Is It safe with alcohol?

  Interaction with alcohol is unknown. Please consult your doctor.

• Are there any pregnancy warnings?

  Advacan 0.5mg tablet is unsafe to use during pregnancy.
  There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk, for example in life-threatening situations. Please consult your doctor.

• Are there any breast-feeding warnings?

  Advacan 0.5mg tablet is probably unsafe to use during breastfeeding. Please consult your doctor.

• Is it safe to drive while on this medicine?

  Caution is advised when driving or operating machinery.

• Does this affect kidney function?

  There is no interaction between renal impairment and consuming this drug. So dose alteration is not needed.

• Does this affect liver function?

  There is no data available. Please consult doctor before consuming the drug.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

Below is the list of medicines, which have the same composition, strength and form as Evergraf 0.25Mg Tablet , and hence can be used as its substitute.

• Certican 0.25Mg Tablet

  Novartis India Ltd

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

This medication behaves similar to that of a signal transduction inhibitor which prevents cells to grow and divide. It is mainly used for treating renal cell cancers and as an immunosuppressant in organ transplantation. It inhibits a protein called mTOR, which is responsible for glucose metabolism and the immune system where it stimulates cancer cells to grow. Therefore, mRNA is impaired affecting the growth of the cancerous tumour.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Oncologist before using this medicine.

• Everolimus-Drug Information Portal [Internet].druginfo.nlm.nih.gov 2022 [Cited 20 June 2022].Available from:

  https://druginfo.nlm.nih.gov/drugportal/name/everolimus

• Everolimus-DrugBank Online [Internet].go.drugbank.com 2022 [Cited 20 June 2022].Available from:

  https://go.drugbank.com/drugs/DB01590

• EVEROLIMUS tablet,solution-DailyMed [Internet].dailymed.nlm.nih.gov 2022 [Cited 20 June 2022].Available from:

  https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=EVEROLIMUS